$160.99 – $354.99
Indication: For the control of clinical signs associated with Pituitary Pars Intermedia Dysfunction (Equine Cushing’s Disease) in horses.
For: oral use in horses only. Pergolide (Prascend) is designated as a class 3 substance by the ARCI.
Active Ingredients: pergolide mesylate
Directions for User: Administer orally at a starting dose of 2 mcg/kg (1 tablet) once daily. Dosage may be adjusted to effect, not to exceed 4 mcg/kg (2 tablets) daily. Prascend Tablets should not be crushed due to the potential for increased human exposure and care should be taken to minimize exposure when splitting tablets. The tablets are scored and the calculated dosage should be provided to the nearest one-half tablet increment. For equine use (horse).
Special Precautions: Do not use in horses intended for human consumption. Keep this and all medications out of the reach of children. Prascend should not be administered by persons who have had adverse reactions to ergotamine or other ergot derivatives. Pregnant or lactating women should wear gloves when administering this product. It has been reported that pergolide tablets may cause eye irritation, an irritating smell, or headache when Prascend Tablets are split or crushed. Prascend Tablets should not be crushed due to the potential for increased human exposure and care should be taken to minimize exposure when splitting tablets. Consult a physician in case of accidental ingestion by humans.